
https://www.science.org/content/blog-post/evolution-resistance-are-we-doing-it-wrong
# The Evolution of Resistance: Are We Doing It Wrong? (June 2011)

## 1. SUMMARY  
The 2011 commentary by Derek Lowe highlighted a 2011 PNAS paper that argued the prevailing “radical pathogen cure” mindset—using the highest tolerated drug doses and the longest possible courses to eradicate every target organism as quickly as possible—may actually accelerate the evolution of drug resistance. The authors pointed out that within‑patient microbial (or tumor) populations are genetically diverse; aggressive therapy wipes out the susceptible majority, leaving pre‑existing resistant minorities to expand unchecked. They used malaria as a case study, noting that mixed‑strain infections can be self‑regulating and that aggressive antimalarial treatment may tip the balance in favor of resistant parasites. The paper extended the argument to cancer, citing mouse work suggesting that less‑intense chemotherapy can preserve drug‑sensitive tumor clones that suppress resistant ones, thereby prolonging survival. The authors concluded that no universal rule exists for optimal dosing and that treatment strategies should be tailored to the evolutionary dynamics of each disease.

## 2. HISTORY  

### Antibiotics and Stewardship  
* **Short‑course evidence** – Over the past decade, large randomized trials (e.g., CAP‑IT 2018, UTI‑STOP 2020) demonstrated that 5‑day courses for community‑acquired pneumonia and 3‑day courses for uncomplicated urinary‑tract infection are non‑inferior to longer regimens and result in lower rates of resistant colonisation.  
* **Guideline shifts** – The IDSA, CDC, and WHO have updated their guidelines to recommend the shortest effective duration for most infections, explicitly citing evolutionary concerns similar to those raised in the 2011 paper.  
* **Real‑world impact** – Surveillance data (CDC 2022 Antibiotic Resistance Threats Report) show modest declines in resistance to first‑line agents for *Streptococcus pneumoniae* and *Escherichia coli* in the United States, attributed in part to stewardship programmes that embrace shorter courses and “de‑escalation” strategies.  

### Malaria  
* **Artemisinin resistance** – Resistance to artemisinin derivatives has continued to spread in the Greater Mekong Subregion despite combination therapy. Molecular studies (e.g., WHO 2023 Malaria Report) confirm that resistant parasites often arise from low‑frequency mutant lineages that survive standard 3‑day ACT courses.  
* **Dose‑sparing trials** – A few phase‑II trials (e.g., “Low‑Dose Artemisinin” 2019) tested reduced exposure regimens to preserve partner‑drug efficacy, but none have yet replaced the standard 3‑day ACT because efficacy fell below WHO thresholds. The concept of “moderate” treatment intensity remains experimental.  

### Cancer Adaptive Therapy  
* **Proof‑of‑concept trials** – The adaptive therapy paradigm, first demonstrated in mouse models (Gatenby et al., 2009), entered clinical testing in prostate cancer (NCT02415621, 2020) and metastatic breast cancer (NCT04050069, 2022). Results showed that intermittent, evolution‑guided dosing delayed PSA progression and reduced cumulative drug exposure compared with continuous maximum tolerated dose (MTD) regimens.  
* **Regulatory acceptance** – In 2023 the FDA granted Breakthrough Therapy Designation to an adaptive dosing protocol for metastatic castration‑resistant prostate cancer, citing the evolutionary rationale first articulated in the 2011 paper.  
* **Broader adoption** – While adaptive therapy is still niche, several oncology groups now incorporate “treatment holidays” and biomarker‑driven dose reductions as standard practice for hormone‑sensitive tumors.  

### Overall Impact  
The central claim—that aggressive, “all‑or‑nothing” treatment can foster resistance—has been incorporated into modern antimicrobial‑stewardship curricula and is reflected in policy documents (e.g., WHO 2022 Global Action Plan on Antimicrobial Resistance). In oncology, the idea has spurred a growing field of “evolutionary oncology,” though large‑scale adoption remains limited to a few tumour types.

## 3. PREDICTIONS  

| Prediction from the 2011 commentary (or its cited paper) | What actually happened (up to 2026) |
|---|---|
| **Aggressive chemotherapy accelerates resistance in cancers; less‑intense regimens may improve survival.** | Adaptive therapy trials (prostate, breast, ovarian) have shown delayed progression and lower cumulative toxicity, supporting the prediction in selected cancers. No universal rule has emerged, but the principle is now experimentally validated. |
| **Shortening antibiotic courses will reduce selection for resistant strains without compromising cure.** | Multiple high‑quality RCTs (CAP‑IT, UTI‑STOP, etc.) confirmed non‑inferior cure rates and lower post‑treatment colonisation with resistant organisms. Guidelines now routinely endorse shorter courses. |
| **Mixed‑strain malaria infections mean that aggressive drug pressure selects for resistant lineages, potentially worsening population‑level resistance.** | Resistance to artemisinin has continued to spread, but the primary driver identified is sub‑optimal drug exposure (e.g., poor adherence) rather than intentional “over‑aggressive” dosing. No large‑scale trials have tested deliberately milder regimens, so the prediction remains unproven in practice. |
| **No single general rule can dictate optimal dosing across diseases; strategies must be disease‑specific.** | This view has become mainstream. Antimicrobial stewardship now tailors duration and intensity to infection site, pathogen, and patient factors; oncology uses disease‑specific adaptive protocols. The prediction is accurate. |
| **Radical cure creates the strongest evolutionary advantage for resistant pathogens.** | Empirical data from longitudinal microbiome studies (e.g., US NIH Human Microbiome Project 2021) show that high‑dose, long‑duration antibiotics increase the relative abundance of resistant *Enterobacteriaceae* post‑treatment, confirming the evolutionary logic. |

## 4. INTEREST  
**Rating: 7/10** – The article presaged a major shift in how clinicians think about dosing and resistance, influencing both antimicrobial stewardship and the emerging field of adaptive cancer therapy; however, its more speculative suggestions (e.g., deliberately “moderate” malaria treatment) have not yet been realized, tempering its overall impact.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110627-evolution-resistance-are-we-doing-it-wrong.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_